VivoSeq
Metabolic & Endocrine

Cushing's Syndrome

0

Pipeline Programs↗

3

Active Trials↗

5

Companies Involved↗

Cushing's Syndrome is an early-stage landscape with 0 programs across 5 companies. The most active players are RECORDATI GROUP, Corcept Therapeutics, Sparrow Pharmaceuticals.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

75/100

Attrition Rate

18/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

R

RECORDATI GROUP

0 programs

PreclinicalC

Corcept Therapeutics

0 programs

PreclinicalS

Sparrow Pharmaceuticals

0 programs

PreclinicalH

HRA Pharma

0 programs

PreclinicalC

Crinetics Pharmaceuticals Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

11

clinical trials

Completed6 · 55%
Recruiting3 · 27%
Terminated2 · 18%

Clinical Trials

Trial Activity

11 trials

Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome
Recruiting·RRECORDATI GROUP·Phase 2·NCT03708900·12 enrolled
Diagnostic Value of CXCR4-targeted PET/CT in ACTH-dependent and Independent Cushing's Syndrome
Recruiting·PPeking Union Medical College Hospital·Phase 1/2·NCT07350707·160 enrolled
A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome
Recruiting·CCrinetics Pharmaceuticals Inc.·Phase 1/2·NCT05804669·18 enrolled
Osilodrostat for the Treatment of Non-Cushing's Disease Cushing's Syndrome
Completed·RRECORDATI GROUP·N/A·NCT05633953·103 enrolled
SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome
Completed·SSparrow Pharmaceuticals·Phase 2·NCT05307328·26 enrolled
Open-label Treatment in Cushing's Syndrome
Completed·CCortendo AB·Phase 3·NCT03621280·51 enrolled
Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition
Completed·UUniversity of Oxford·Phase 2·NCT03111810·32 enrolled
Study to Evaluate CORT125134 in Participants With Cushing's Syndrome
Completed·CCorcept Therapeutics·Phase 2·NCT02804750·35 enrolled
Definition of the Genotype and Clinical Phenotype of Primary Pigmented Nodular Adrenocortical Disease (PPNAD), Carney Complex, Peutz-Jeghers Syndrome and Related Conditions
Completed·Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·N/A·NCT00001452·1,387 enrolled
A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of Hypercortisolemia
Terminated·CCorcept Therapeutics·N/A·NCT00796783·2 enrolled
Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion
Terminated·HHRA Pharma·Phase 2·NCT00422201·18 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)